Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today that it entered into a strategic research collaboration with Beta Therapeutics Pty Ltd (Canberra, Australia) to develop new heparanase inhibitors for the treatment of retinal disorders with large unmet medical needs such as dry age-related macular degeneration.
Under the terms of the agreement Oxurion will have an exclusive option to license in the heparanase inhibitor program. Beta Therapeutics will receive an undisclosed upfront payment from Oxurion and is eligible to receive a payment upon exercising the licensing option, development, regulatory and commercial milestone payments, as well as royalties on net sales on the products developed under the partnership.
Full press release: https://www.prnewswire.com/news-releases/oxurion-and-beta-therapeutics-to-develop-new-heparanase-inhibitors-for-treatment-of-dry-amd-803387243.html